THE BIOCELECT TEAM
Our expertise available to meet your needs
Karl has over 25 years of varied experience in the pharmaceutical industry – from the lab to senior management.
He has extensive marketing and commercial experience with major companies such as GSK, Sanofi and Sigma Pharmaceuticals, as well as start-ups like Generic Health; a subsidiary of Lupin Pharmaceuticals.
Karl is also a Director of Biocelect's sister company; Biointelect.
Karl has a wide experience across a number of therapeutic areas, including oncology, cardiovascular disease and diabetes.
He graduated with a degree in Biomedicine from UTS, majoring in biochemistry and microbiology and a post graduate certificate in marketing.
Jennifer Herz is the Managing Director of Biocelect's sister company; Biointelect, which she founded in 2011 to provide strategic commercialisation services to the biopharmaceutical industry. Jennifer has over twenty years commercial, business development and scientific affairs experience in the biopharmaceutical industry and has held a variety of roles with responsibility for Australia, New Zealand and European markets. She was the first Managing Director of Sanofi Pasteur in Australia which was a start-up company and grew significantly over the 6 years of her tenure to be an established major provider of vaccines to the public and private market in Australia, New Zealand and the Pacific Region.
She has previously served on the Board of Medicines Australia where she led industry discussions with government related to the new funding arrangements for vaccines on the PBAC. She was also active in a variety of European and International Industry Association working groups responsible for liaison with health authorities including European Institutions and the WHO. She is a member of the Accelerate Commercialisation Expert Network, on the Steering Committee of the NHMRC funded Centre of Research Excellence: Policy relevant infectious disease simulation and mathematical modelling (PRISM) and is a member of the Expert Reference Group of the Australian Partnership for Preparedness Research on Infectious Disease Emergencies (APPRISE). Jennifer has an extensive international & local network of industry, policy, scientific and clinical experts across many therapeutic areas and healthcare sectors along with global experience in multiple new product launches and start-ups at all stages of development.
Chief Financial Officer
Max Howell has over fifteen years of pharmaceutical industry experience in senior Finance roles in Australia and Indonesia. Additionally, a similar period in speciality chemicals and wine industry meaning over thirty years’ experience in Finance roles in major multinational companies.
He graduated from the Australian National University in Canberra in Economics majoring in both Economics and Accounting. He is a member of CPA Australia (Certified Practising Accountant).
Max joined RPR in Australia at the time of the Aventis merger with HMR in a project role to rationalise local industrial facilities and helped to establish site sale and establishment of long-term third-party toll manufacturing agreements. Following this role and a period in Commercial Operations in the local Aventis entity Max undertook the CFO role for the Aventis entity in Indonesia, based in Jakarta. He held responsibility over Finance, IS and Distribution as well as dealings with local external shareholders. After the global Sanofi Aventis merger, he took local responsibility for the integration of the two Indonesian businesses including shareholder rationalisation.
Later he returned to Australia as the local Finance and Operations Director for Sanofi’s vaccine business Sanofi Pasteur. Responsible for Finance, IS and Supply Chain, he participated as the Finance and Legal lead on the project team that was successful in negotiating the first Australian sale of Pandemic (H5N1) vaccine to the Australian Government.
In his final roles with Sanofi he focused on project management within Pasteur as well as Sanofi’s animal health business Merial, restructuring finance and supply chain and customer service functions into shared service environments including offshore regional finance centres.
National Key Account Manager
Jeff is an accomplished senior health executive with over 20 years of experience in the pharmaceutical industry in both the UK and Australia.
He held sales roles at Astra, 3M and Warner Lambert Pharmaceuticals where he gained experience in numerous therapeutic areas, including cardiovascular, respiratory and gastrointestinal health.
During his 18 year tenure at GlaxoSmithKline he worked mostly in the Vaccines Business Unit. As a Travel Vaccines Key Account Manager, he gained experience with corporate travel clinics, surgical and pharmacy wholesalers, primary care and hospital channels. Most recently, he held the role of National Immunisation Program Regional Manager, where he worked in partnership with State and Territory governments, State Based Organisations, Primary Health Networks, Aboriginal Health/Medical Services, Hospitals and other immunisation providers.
He holds a BSc (Business Administration) from the University of Wales.
Emily Herz joined Biocelect in 2020 in a customer support, new product planning role and sales position. She also manages marketing and website development. She has a strong customer service mind-set and a broad working knowledge of Biocelect operations.
Prior to this Emily spent 4 years in retail pharmacy and 3 years at MECCA Brands, where she was responsible for customer service, managing stock and merchandising. Emily speaks French fluently, has creative flair and is also a qualified makeup artist.
Emily brings her organisational skills and health care sector knowledge to support both internal and external customers at Biocelect. She is passionate about small business and building pathways to patients for new products in Australia.